One of the mas­ter­minds be­hind remde­sivir, Gilead­'s Di­ana Brainard jumps ship to an­tivi­ral T cell play­er AlloVir

As one of the star­tups tapped to join David Hal­lal’s dis­rup­tive man­u­fac­tur­ing out­fit El­e­vate­Bio in the Boston area, AlloVir has built an ag­gres­sive clin­i­cal pro­gram for its virus-spe­cif­ic T cells. Now, the biotech is tap­ping as chief a Gilead vet­er­an with her own ex­pe­ri­ence rac­ing a high­ly tout­ed an­tivi­ral to mar­ket.

Di­ana Brainard, one of the key dri­vers be­hind Gilead’s push to se­cure an emer­gency use au­tho­riza­tion for an­tivi­ral remde­sivir in Covid-19, will take over as CEO of the up­start vi­ral play­er on May 17.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER